Understanding how antibodies can protect against major respiratory viruses in cancer patients
Official title: Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses
Funded at Fred Hutchinson Cancer Center · NIH-11041096 · Data updated 2026-11-12
This study is looking at how well certain antibodies can help protect people who have had a stem cell transplant from serious respiratory infections caused by four common viruses, making it safer for them after their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | March 16, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $708,446 |
| NIH project number | 5R01AI171186-03 |
| Project ID | NIH-11041096 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults who have recently undergone hematopoietic stem cell transplantation and are at risk for viral respiratory infections.
✕Less likely to help
Patients who are not undergoing hematopoietic stem cell transplantation or those with intact immune systems may not benefit from this research.
What this research studies
This research investigates the effectiveness of cross-neutralizing antibodies in preventing severe respiratory infections caused by four major viruses in patients who have undergone hematopoietic stem cell transplantation (HCT). The study aims to identify and develop monoclonal antibodies that can provide protection against these viruses, which are particularly dangerous for HCT recipients due to their compromised immune systems. By focusing on the molecular interactions between these antibodies and the viruses, the research seeks to enhance patient safety and outcomes post-transplant. The approach includes laboratory studies and potential clinical applications to evaluate the efficacy of these antibodies in real-world scenarios.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of life-threatening respiratory infections in patients recovering from cancer treatment.
How similar studies have gone: Previous research has shown promise in using monoclonal antibodies for viral infections, but this specific approach targeting multiple respiratory viruses in HCT patients is novel.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Boonyaratanakornkit, Jim — Fred Hutchinson Cancer Center
- Study coordinator: Boonyaratanakornkit, Jim
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.